Saving Lives through Critical Medicines

Dedicated to Helping Patients Overcome Cancer

Sauvie aspires to be a premier global biopharma company to significantly alter or cure cancer progression and be a meaningful and positive participant in a patient’s journey to overcome their disease.

Latest News

Sauvie Inc. Enters into an Exclusive Worldwide License Agreement to Develop and Commercialize a Nanobody-based NK Cell Engager

SHORT HILLS, N.J., Oct. 24, 2022/PRNewswire/ – Sauvie Inc. (the “Company”), a mission-driven biopharmaceutical company focused on sustainably building an immuno-oncology company, today announced Sauvie’s subsidiary, Sauvie BiKE LLC, has entered into an exclusive license agreement with Rutgers, The State University of New Jersey (“Rutgers”) for the development and worldwide commercialization rights of a bi-specific natural killer (NK) cell engager technology in the field of oncology.

Sauvie is a mission-driven biopharmaceutical company executing a diversified risk, high growth strategy.